RAY1225
The Safety, Tolerability and Pharmacokinetic Study of RAY1225
Guangdong Raynovent Biotech Co · Phase 1 · Completed · Enrollment 68
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| RAY1225(Part A) | Obese; Healthy | n/r | n/r | n/r | n/r |
| Placebo (Part A) | Obese; Healthy | n/r | n/r | n/r | n/r |
| RAY1225 (Part B) | Obese; Healthy | n/r | n/r | n/r | n/r |
| Placebo (Part B) | Obese; Healthy | n/r | n/r | n/r | n/r |
| RAY1225(Part C) | Obese; Healthy | n/r | n/r | n/r | n/r |
| Placebo (Part C) | Obese; Healthy | n/r | n/r | n/r | n/r |